Hormone manipulation has long been the cornerstone of advanced prostate cancer management, but the cardiovascular toll of conventional androgen deprivation therapy remains a persistent clinical problem. A correspondence published in the New England Journal of Medicine revisits an older hormonal strategy — transdermal estradiol delivery — as a potentially safer alternative that preserves testosterone suppression while avoiding the metabolic penalties associated with luteinizing hormone-releasing hormone agonists.
The item, appearing in NEJM Volume 395 (July 2026), addresses the use of estradiol patches as a method of achieving castrate-level testosterone in prostate cancer patients. Unlike oral estrogen formulations, transdermal delivery bypasses first-pass hepatic metabolism, which is believed to be responsible for the thromboembolic and cardiovascular events that historically derailed estrogen-based prostate cancer treatment. The patch format maintains steady systemic estradiol levels sufficient to suppress the hypothalamic-pituitary-gonadal axis, theoretically replicating the androgen suppression of standard medical castration without the bone density loss, hot flashes, and lipid dysregulation characteristic of LHRH-based therapy.
This approach is not entirely new — the PATCH trial in the UK evaluated transdermal estradiol against LHRH agonists and reported comparable oncological efficacy with a more favorable cardiovascular and metabolic profile. What makes continued attention in a flagship journal significant is the persistent unmet need: androgen deprivation therapy is among the most metabolically disruptive long-term treatments in oncology, with documented associations with diabetes, sarcopenia, and cardiovascular mortality. The transdermal estradiol strategy directly challenges the assumption that estrogen-based androgen suppression is obsolete. That said, this is a brief correspondence rather than a primary trial, limiting the strength of conclusions. Broader adoption would require confirmatory Phase III data and longer follow-up on cardiovascular endpoints. For now, it represents a clinically plausible, underutilized option warranting serious re-evaluation.